DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Hubballi: The department of health research, govt of India, commended three multidisciplinary research units (MRU) at govt ...

The Department of Pharmaceuticals, Government of India, hosted an Industry Dialogue on the scheme for Promotion of Research ...

Nandita Vijayasimha, Bengaluru Saturday, March 29, 2025, 08:00 Hrs [IST] ...

Research and Development (“R&D”) Expenses : R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due ...

The Exosome Therapeutics Market is projected to grow from $30 million in 2029 to $1.4 billion by 2040, at a CAGR of 41.1%.